Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
9,144
archived clinical trials in
Ocular

Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis
A 38-week Extension to a 24-week Multicenter, Randomized, Double-masked, Placebo Controlled, Dose-ranging Phase III Study of AIN457 Versus Placebo for Maintaining Uveitis Suppression When Reducing Systemic Immunosuppression in Patients With Quiescent, Non-infectious Intermediate, Posterior or Panuveitis
Status: Enrolling
Updated:  12/8/2015
Novartis Investigative Site
mi
from
Cambridge, MA
Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis
A 38-week Extension to a 24-week Multicenter, Randomized, Double-masked, Placebo Controlled, Dose-ranging Phase III Study of AIN457 Versus Placebo for Maintaining Uveitis Suppression When Reducing Systemic Immunosuppression in Patients With Quiescent, Non-infectious Intermediate, Posterior or Panuveitis
Status: Enrolling
Updated: 12/8/2015
Novartis Investigative Site
mi
from
Cambridge, MA
Click here to add this to my saved trials
Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis
A 38-week Extension to a 24-week Multicenter, Randomized, Double-masked, Placebo Controlled, Dose-ranging Phase III Study of AIN457 Versus Placebo for Maintaining Uveitis Suppression When Reducing Systemic Immunosuppression in Patients With Quiescent, Non-infectious Intermediate, Posterior or Panuveitis
Status: Enrolling
Updated:  12/8/2015
Novartis Investigative Site
mi
from
Teaneck, NJ
Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis
A 38-week Extension to a 24-week Multicenter, Randomized, Double-masked, Placebo Controlled, Dose-ranging Phase III Study of AIN457 Versus Placebo for Maintaining Uveitis Suppression When Reducing Systemic Immunosuppression in Patients With Quiescent, Non-infectious Intermediate, Posterior or Panuveitis
Status: Enrolling
Updated: 12/8/2015
Novartis Investigative Site
mi
from
Teaneck, NJ
Click here to add this to my saved trials
Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis
A 38-week Extension to a 24-week Multicenter, Randomized, Double-masked, Placebo Controlled, Dose-ranging Phase III Study of AIN457 Versus Placebo for Maintaining Uveitis Suppression When Reducing Systemic Immunosuppression in Patients With Quiescent, Non-infectious Intermediate, Posterior or Panuveitis
Status: Enrolling
Updated:  12/8/2015
Novartis Investigative Site
mi
from
Charlotte, NC
Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis
A 38-week Extension to a 24-week Multicenter, Randomized, Double-masked, Placebo Controlled, Dose-ranging Phase III Study of AIN457 Versus Placebo for Maintaining Uveitis Suppression When Reducing Systemic Immunosuppression in Patients With Quiescent, Non-infectious Intermediate, Posterior or Panuveitis
Status: Enrolling
Updated: 12/8/2015
Novartis Investigative Site
mi
from
Charlotte, NC
Click here to add this to my saved trials
Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis
A 38-week Extension to a 24-week Multicenter, Randomized, Double-masked, Placebo Controlled, Dose-ranging Phase III Study of AIN457 Versus Placebo for Maintaining Uveitis Suppression When Reducing Systemic Immunosuppression in Patients With Quiescent, Non-infectious Intermediate, Posterior or Panuveitis
Status: Enrolling
Updated:  12/8/2015
Novartis
mi
from
Portland, OR
Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis
A 38-week Extension to a 24-week Multicenter, Randomized, Double-masked, Placebo Controlled, Dose-ranging Phase III Study of AIN457 Versus Placebo for Maintaining Uveitis Suppression When Reducing Systemic Immunosuppression in Patients With Quiescent, Non-infectious Intermediate, Posterior or Panuveitis
Status: Enrolling
Updated: 12/8/2015
Novartis
mi
from
Portland, OR
Click here to add this to my saved trials
Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis
A 38-week Extension to a 24-week Multicenter, Randomized, Double-masked, Placebo Controlled, Dose-ranging Phase III Study of AIN457 Versus Placebo for Maintaining Uveitis Suppression When Reducing Systemic Immunosuppression in Patients With Quiescent, Non-infectious Intermediate, Posterior or Panuveitis
Status: Enrolling
Updated:  12/8/2015
Novartis Investigative Site
mi
from
Arlington, TX
Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis
A 38-week Extension to a 24-week Multicenter, Randomized, Double-masked, Placebo Controlled, Dose-ranging Phase III Study of AIN457 Versus Placebo for Maintaining Uveitis Suppression When Reducing Systemic Immunosuppression in Patients With Quiescent, Non-infectious Intermediate, Posterior or Panuveitis
Status: Enrolling
Updated: 12/8/2015
Novartis Investigative Site
mi
from
Arlington, TX
Click here to add this to my saved trials
Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis
A 38-week Extension to a 24-week Multicenter, Randomized, Double-masked, Placebo Controlled, Dose-ranging Phase III Study of AIN457 Versus Placebo for Maintaining Uveitis Suppression When Reducing Systemic Immunosuppression in Patients With Quiescent, Non-infectious Intermediate, Posterior or Panuveitis
Status: Enrolling
Updated:  12/8/2015
Novartis Investigative Site
mi
from
Houston, TX
Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis
A 38-week Extension to a 24-week Multicenter, Randomized, Double-masked, Placebo Controlled, Dose-ranging Phase III Study of AIN457 Versus Placebo for Maintaining Uveitis Suppression When Reducing Systemic Immunosuppression in Patients With Quiescent, Non-infectious Intermediate, Posterior or Panuveitis
Status: Enrolling
Updated: 12/8/2015
Novartis Investigative Site
mi
from
Houston, TX
Click here to add this to my saved trials
Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis
A 38-week Extension to a 24-week Multicenter, Randomized, Double-masked, Placebo Controlled, Dose-ranging Phase III Study of AIN457 Versus Placebo for Maintaining Uveitis Suppression When Reducing Systemic Immunosuppression in Patients With Quiescent, Non-infectious Intermediate, Posterior or Panuveitis
Status: Enrolling
Updated:  12/8/2015
Novartis Investigative Site
mi
from
Sao Paulo,
Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis
A 38-week Extension to a 24-week Multicenter, Randomized, Double-masked, Placebo Controlled, Dose-ranging Phase III Study of AIN457 Versus Placebo for Maintaining Uveitis Suppression When Reducing Systemic Immunosuppression in Patients With Quiescent, Non-infectious Intermediate, Posterior or Panuveitis
Status: Enrolling
Updated: 12/8/2015
Novartis Investigative Site
mi
from
Sao Paulo,
Click here to add this to my saved trials
Comparing the Effect of the Water Drinking Test on Intraocular Pressure
Comparing the Effect of the Water Drinking Test on Intraocular Pressure in Patients With Prior Trabeculectomy or Tube Shunt Surgeries
Status: Enrolling
Updated:  12/8/2015
Wills Eye Hospital
mi
from
Philadelphia, PA
Comparing the Effect of the Water Drinking Test on Intraocular Pressure
Comparing the Effect of the Water Drinking Test on Intraocular Pressure in Patients With Prior Trabeculectomy or Tube Shunt Surgeries
Status: Enrolling
Updated: 12/8/2015
Wills Eye Hospital
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subjects With Glaucoma or Ocular Hypertension
Status: Enrolling
Updated:  12/9/2015
Clinical Research Facility
mi
from
Racine, WI
Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subjects With Glaucoma or Ocular Hypertension
Status: Enrolling
Updated: 12/9/2015
Clinical Research Facility
mi
from
Racine, WI
Click here to add this to my saved trials
Building a Database of Results From People Without Eye Problems
A Prospective Study of Controls to Build a Normative Database for the Spaeth/Richman Contrast Sensitivity Test (SPARCS)
Status: Enrolling
Updated:  12/9/2015
Wills Eye Glaucoma Service
mi
from
Philadelphia, PA
Building a Database of Results From People Without Eye Problems
A Prospective Study of Controls to Build a Normative Database for the Spaeth/Richman Contrast Sensitivity Test (SPARCS)
Status: Enrolling
Updated: 12/9/2015
Wills Eye Glaucoma Service
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Moxifloxacin vs. Polytrim for Conjunctivitis
A Single Blinded Clinical Trial Comparing Polytrim Ophthalmic Solution and Moxifloxacin Ophthalmic Solution for Treatment of Conjunctivitis.
Status: Enrolling
Updated:  12/11/2015
University of Rochester
mi
from
Rochester, NY
Moxifloxacin vs. Polytrim for Conjunctivitis
A Single Blinded Clinical Trial Comparing Polytrim Ophthalmic Solution and Moxifloxacin Ophthalmic Solution for Treatment of Conjunctivitis.
Status: Enrolling
Updated: 12/11/2015
University of Rochester
mi
from
Rochester, NY
Click here to add this to my saved trials
The Effects of Xalatan, Travatan and Lumigan on Skin Pigmentation Near the Eye
The Effects of Latanoprost, Bimatoprost and Travoprost on Periocular Skin Pigmentation
Status: Enrolling
Updated:  12/14/2015
Arlington Eye Physicians
mi
from
Arlington Heights, IL
The Effects of Xalatan, Travatan and Lumigan on Skin Pigmentation Near the Eye
The Effects of Latanoprost, Bimatoprost and Travoprost on Periocular Skin Pigmentation
Status: Enrolling
Updated: 12/14/2015
Arlington Eye Physicians
mi
from
Arlington Heights, IL
Click here to add this to my saved trials
The Effects of Xalatan, Travatan and Lumigan on Skin Pigmentation Near the Eye
The Effects of Latanoprost, Bimatoprost and Travoprost on Periocular Skin Pigmentation
Status: Enrolling
Updated:  12/14/2015
Summa Health System
mi
from
Akron, OH
The Effects of Xalatan, Travatan and Lumigan on Skin Pigmentation Near the Eye
The Effects of Latanoprost, Bimatoprost and Travoprost on Periocular Skin Pigmentation
Status: Enrolling
Updated: 12/14/2015
Summa Health System
mi
from
Akron, OH
Click here to add this to my saved trials
Diabetic Macular Edema Treated With Ozurdex (DMEO)
Diabetic Macular Edema Treated With Ozurdex (DMEO)
Status: Enrolling
Updated:  12/15/2015
Wilmer Eye Institute
mi
from
Baltimore, MD
Diabetic Macular Edema Treated With Ozurdex (DMEO)
Diabetic Macular Edema Treated With Ozurdex (DMEO)
Status: Enrolling
Updated: 12/15/2015
Wilmer Eye Institute
mi
from
Baltimore, MD
Click here to add this to my saved trials
Propranolol for Diabetic Retinopathy
Propranolol for Diabetic Retinopathy
Status: Enrolling
Updated:  12/17/2015
University of Wisconsin-Madison
mi
from
Madison, WI
Propranolol for Diabetic Retinopathy
Propranolol for Diabetic Retinopathy
Status: Enrolling
Updated: 12/17/2015
University of Wisconsin-Madison
mi
from
Madison, WI
Click here to add this to my saved trials
Computer Vision System for the Blind Veteran
Computer Vision System for the Blind Veteran
Status: Enrolling
Updated:  12/18/2015
Atlanta VA Medical and Rehab Center, Decatur
mi
from
Decatur, GA
Computer Vision System for the Blind Veteran
Computer Vision System for the Blind Veteran
Status: Enrolling
Updated: 12/18/2015
Atlanta VA Medical and Rehab Center, Decatur
mi
from
Decatur, GA
Click here to add this to my saved trials
Computer Vision System for the Blind Veteran
Computer Vision System for the Blind Veteran
Status: Enrolling
Updated:  12/18/2015
Baltimore VA Medical Center VA Maryland Health Care System, Baltimore, MD
mi
from
Baltimore, MD
Computer Vision System for the Blind Veteran
Computer Vision System for the Blind Veteran
Status: Enrolling
Updated: 12/18/2015
Baltimore VA Medical Center VA Maryland Health Care System, Baltimore, MD
mi
from
Baltimore, MD
Click here to add this to my saved trials
Comparative Study of Thymosin Beta 4 Eye Drops vs. Vehicle in the Treatment of Severe Dry Eye
Comparative Study of Thymosin Beta 4 Eye Drops or Vehicle in the Treatment of Patients With Ocular Surface Defects Due to Severe Dry Eye
Status: Enrolling
Updated:  12/21/2015
Michigan Cornea Consultants, P.C.
mi
from
Southfield, MI
Comparative Study of Thymosin Beta 4 Eye Drops vs. Vehicle in the Treatment of Severe Dry Eye
Comparative Study of Thymosin Beta 4 Eye Drops or Vehicle in the Treatment of Patients With Ocular Surface Defects Due to Severe Dry Eye
Status: Enrolling
Updated: 12/21/2015
Michigan Cornea Consultants, P.C.
mi
from
Southfield, MI
Click here to add this to my saved trials
IOP Fluctuations in Patients With Sleep Apnea With or Without Primary Open Angle Glaucoma Using Positive Airway Pressure
A Prospective, Explorative, Open Label Study to Assess the 24-hour Intraocular Pressure Fluctuation Profile Recorded With SENSIMED Triggerfish® in Patients With Moderate to Severe Obstructive Sleep Apnea Syndrome Using Continuous Positive Airway Pressure With or Without Primary Open Angle Glaucoma
Status: Enrolling
Updated:  12/21/2015
The New York Eye and Ear Infirmary
mi
from
New-York, NY
IOP Fluctuations in Patients With Sleep Apnea With or Without Primary Open Angle Glaucoma Using Positive Airway Pressure
A Prospective, Explorative, Open Label Study to Assess the 24-hour Intraocular Pressure Fluctuation Profile Recorded With SENSIMED Triggerfish® in Patients With Moderate to Severe Obstructive Sleep Apnea Syndrome Using Continuous Positive Airway Pressure With or Without Primary Open Angle Glaucoma
Status: Enrolling
Updated: 12/21/2015
The New York Eye and Ear Infirmary
mi
from
New-York, NY
Click here to add this to my saved trials
Effect of Ruboxistaurin on Clinically Significant Macular Edema
The Effect of Ruboxistaurin on Vision Loss in Patients With Diabetes Mellitus and Clinically Significant Macular Edema
Status: Enrolling
Updated:  12/22/2015
Clinical Research Facility
mi
from
Phoenix, AZ
Effect of Ruboxistaurin on Clinically Significant Macular Edema
The Effect of Ruboxistaurin on Vision Loss in Patients With Diabetes Mellitus and Clinically Significant Macular Edema
Status: Enrolling
Updated: 12/22/2015
Clinical Research Facility
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Effect of Ruboxistaurin on Clinically Significant Macular Edema
The Effect of Ruboxistaurin on Vision Loss in Patients With Diabetes Mellitus and Clinically Significant Macular Edema
Status: Enrolling
Updated:  12/22/2015
Clinical Research Facility
mi
from
Artesia, CA
Effect of Ruboxistaurin on Clinically Significant Macular Edema
The Effect of Ruboxistaurin on Vision Loss in Patients With Diabetes Mellitus and Clinically Significant Macular Edema
Status: Enrolling
Updated: 12/22/2015
Clinical Research Facility
mi
from
Artesia, CA
Click here to add this to my saved trials
Effect of Ruboxistaurin on Clinically Significant Macular Edema
The Effect of Ruboxistaurin on Vision Loss in Patients With Diabetes Mellitus and Clinically Significant Macular Edema
Status: Enrolling
Updated:  12/22/2015
Clinical Research Facility
mi
from
Newark, DE
Effect of Ruboxistaurin on Clinically Significant Macular Edema
The Effect of Ruboxistaurin on Vision Loss in Patients With Diabetes Mellitus and Clinically Significant Macular Edema
Status: Enrolling
Updated: 12/22/2015
Clinical Research Facility
mi
from
Newark, DE
Click here to add this to my saved trials
Effect of Ruboxistaurin on Clinically Significant Macular Edema
The Effect of Ruboxistaurin on Vision Loss in Patients With Diabetes Mellitus and Clinically Significant Macular Edema
Status: Enrolling
Updated:  12/22/2015
Clinical Research Facility
mi
from
Jacksonville, FL
Effect of Ruboxistaurin on Clinically Significant Macular Edema
The Effect of Ruboxistaurin on Vision Loss in Patients With Diabetes Mellitus and Clinically Significant Macular Edema
Status: Enrolling
Updated: 12/22/2015
Clinical Research Facility
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Effect of Ruboxistaurin on Clinically Significant Macular Edema
The Effect of Ruboxistaurin on Vision Loss in Patients With Diabetes Mellitus and Clinically Significant Macular Edema
Status: Enrolling
Updated:  12/22/2015
Clinical Research Facility
mi
from
Augusta, GA
Effect of Ruboxistaurin on Clinically Significant Macular Edema
The Effect of Ruboxistaurin on Vision Loss in Patients With Diabetes Mellitus and Clinically Significant Macular Edema
Status: Enrolling
Updated: 12/22/2015
Clinical Research Facility
mi
from
Augusta, GA
Click here to add this to my saved trials
Effect of Ruboxistaurin on Clinically Significant Macular Edema
The Effect of Ruboxistaurin on Vision Loss in Patients With Diabetes Mellitus and Clinically Significant Macular Edema
Status: Enrolling
Updated:  12/22/2015
Clinical Research Facility
mi
from
Indianapolis, IN
Effect of Ruboxistaurin on Clinically Significant Macular Edema
The Effect of Ruboxistaurin on Vision Loss in Patients With Diabetes Mellitus and Clinically Significant Macular Edema
Status: Enrolling
Updated: 12/22/2015
Clinical Research Facility
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Effect of Ruboxistaurin on Clinically Significant Macular Edema
The Effect of Ruboxistaurin on Vision Loss in Patients With Diabetes Mellitus and Clinically Significant Macular Edema
Status: Enrolling
Updated:  12/22/2015
Clinical Research Facility
mi
from
Baltimore, MD
Effect of Ruboxistaurin on Clinically Significant Macular Edema
The Effect of Ruboxistaurin on Vision Loss in Patients With Diabetes Mellitus and Clinically Significant Macular Edema
Status: Enrolling
Updated: 12/22/2015
Clinical Research Facility
mi
from
Baltimore, MD
Click here to add this to my saved trials
Effect of Ruboxistaurin on Clinically Significant Macular Edema
The Effect of Ruboxistaurin on Vision Loss in Patients With Diabetes Mellitus and Clinically Significant Macular Edema
Status: Enrolling
Updated:  12/22/2015
Clinical Research Facility
mi
from
Boston, MA
Effect of Ruboxistaurin on Clinically Significant Macular Edema
The Effect of Ruboxistaurin on Vision Loss in Patients With Diabetes Mellitus and Clinically Significant Macular Edema
Status: Enrolling
Updated: 12/22/2015
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
Effect of Ruboxistaurin on Clinically Significant Macular Edema
The Effect of Ruboxistaurin on Vision Loss in Patients With Diabetes Mellitus and Clinically Significant Macular Edema
Status: Enrolling
Updated:  12/22/2015
Clinical Research Facility
mi
from
Grand Rapids, MI
Effect of Ruboxistaurin on Clinically Significant Macular Edema
The Effect of Ruboxistaurin on Vision Loss in Patients With Diabetes Mellitus and Clinically Significant Macular Edema
Status: Enrolling
Updated: 12/22/2015
Clinical Research Facility
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
Effect of Ruboxistaurin on Clinically Significant Macular Edema
The Effect of Ruboxistaurin on Vision Loss in Patients With Diabetes Mellitus and Clinically Significant Macular Edema
Status: Enrolling
Updated:  12/22/2015
Clinical Research Facility
mi
from
Portsmouth, NH
Effect of Ruboxistaurin on Clinically Significant Macular Edema
The Effect of Ruboxistaurin on Vision Loss in Patients With Diabetes Mellitus and Clinically Significant Macular Edema
Status: Enrolling
Updated: 12/22/2015
Clinical Research Facility
mi
from
Portsmouth, NH
Click here to add this to my saved trials
Effect of Ruboxistaurin on Clinically Significant Macular Edema
The Effect of Ruboxistaurin on Vision Loss in Patients With Diabetes Mellitus and Clinically Significant Macular Edema
Status: Enrolling
Updated:  12/22/2015
Clinical Research Facility
mi
from
Slingerlands, NY
Effect of Ruboxistaurin on Clinically Significant Macular Edema
The Effect of Ruboxistaurin on Vision Loss in Patients With Diabetes Mellitus and Clinically Significant Macular Edema
Status: Enrolling
Updated: 12/22/2015
Clinical Research Facility
mi
from
Slingerlands, NY
Click here to add this to my saved trials
Effect of Ruboxistaurin on Clinically Significant Macular Edema
The Effect of Ruboxistaurin on Vision Loss in Patients With Diabetes Mellitus and Clinically Significant Macular Edema
Status: Enrolling
Updated:  12/22/2015
Clinical Research Facility
mi
from
Asheville, NC
Effect of Ruboxistaurin on Clinically Significant Macular Edema
The Effect of Ruboxistaurin on Vision Loss in Patients With Diabetes Mellitus and Clinically Significant Macular Edema
Status: Enrolling
Updated: 12/22/2015
Clinical Research Facility
mi
from
Asheville, NC
Click here to add this to my saved trials
Effect of Ruboxistaurin on Clinically Significant Macular Edema
The Effect of Ruboxistaurin on Vision Loss in Patients With Diabetes Mellitus and Clinically Significant Macular Edema
Status: Enrolling
Updated:  12/22/2015
Clinical Research Facility
mi
from
Lakewood, OH
Effect of Ruboxistaurin on Clinically Significant Macular Edema
The Effect of Ruboxistaurin on Vision Loss in Patients With Diabetes Mellitus and Clinically Significant Macular Edema
Status: Enrolling
Updated: 12/22/2015
Clinical Research Facility
mi
from
Lakewood, OH
Click here to add this to my saved trials
Effect of Ruboxistaurin on Clinically Significant Macular Edema
The Effect of Ruboxistaurin on Vision Loss in Patients With Diabetes Mellitus and Clinically Significant Macular Edema
Status: Enrolling
Updated:  12/22/2015
Clinical Research Facility
mi
from
Kingston, PA
Effect of Ruboxistaurin on Clinically Significant Macular Edema
The Effect of Ruboxistaurin on Vision Loss in Patients With Diabetes Mellitus and Clinically Significant Macular Edema
Status: Enrolling
Updated: 12/22/2015
Clinical Research Facility
mi
from
Kingston, PA
Click here to add this to my saved trials
Effect of Ruboxistaurin on Clinically Significant Macular Edema
The Effect of Ruboxistaurin on Vision Loss in Patients With Diabetes Mellitus and Clinically Significant Macular Edema
Status: Enrolling
Updated:  12/22/2015
Clinical Research Facility
mi
from
Pittsburgh, PA
Effect of Ruboxistaurin on Clinically Significant Macular Edema
The Effect of Ruboxistaurin on Vision Loss in Patients With Diabetes Mellitus and Clinically Significant Macular Edema
Status: Enrolling
Updated: 12/22/2015
Clinical Research Facility
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Effect of Ruboxistaurin on Clinically Significant Macular Edema
The Effect of Ruboxistaurin on Vision Loss in Patients With Diabetes Mellitus and Clinically Significant Macular Edema
Status: Enrolling
Updated:  12/22/2015
Clinical Research Facility
mi
from
West Mifflin, PA
Effect of Ruboxistaurin on Clinically Significant Macular Edema
The Effect of Ruboxistaurin on Vision Loss in Patients With Diabetes Mellitus and Clinically Significant Macular Edema
Status: Enrolling
Updated: 12/22/2015
Clinical Research Facility
mi
from
West Mifflin, PA
Click here to add this to my saved trials
Effect of Ruboxistaurin on Clinically Significant Macular Edema
The Effect of Ruboxistaurin on Vision Loss in Patients With Diabetes Mellitus and Clinically Significant Macular Edema
Status: Enrolling
Updated:  12/22/2015
Clinical Research Facility
mi
from
Dallas, TX
Effect of Ruboxistaurin on Clinically Significant Macular Edema
The Effect of Ruboxistaurin on Vision Loss in Patients With Diabetes Mellitus and Clinically Significant Macular Edema
Status: Enrolling
Updated: 12/22/2015
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
Effect of Ruboxistaurin on Clinically Significant Macular Edema
The Effect of Ruboxistaurin on Vision Loss in Patients With Diabetes Mellitus and Clinically Significant Macular Edema
Status: Enrolling
Updated:  12/22/2015
Clinical Research Facility
mi
from
Houston, TX
Effect of Ruboxistaurin on Clinically Significant Macular Edema
The Effect of Ruboxistaurin on Vision Loss in Patients With Diabetes Mellitus and Clinically Significant Macular Edema
Status: Enrolling
Updated: 12/22/2015
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Effect of Ruboxistaurin on Clinically Significant Macular Edema
The Effect of Ruboxistaurin on Vision Loss in Patients With Diabetes Mellitus and Clinically Significant Macular Edema
Status: Enrolling
Updated:  12/22/2015
Clinical Research Facility
mi
from
San Antonio, TX
Effect of Ruboxistaurin on Clinically Significant Macular Edema
The Effect of Ruboxistaurin on Vision Loss in Patients With Diabetes Mellitus and Clinically Significant Macular Edema
Status: Enrolling
Updated: 12/22/2015
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
Effect of Ruboxistaurin on Clinically Significant Macular Edema
The Effect of Ruboxistaurin on Vision Loss in Patients With Diabetes Mellitus and Clinically Significant Macular Edema
Status: Enrolling
Updated:  12/22/2015
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
mi
from
Halifax,
Effect of Ruboxistaurin on Clinically Significant Macular Edema
The Effect of Ruboxistaurin on Vision Loss in Patients With Diabetes Mellitus and Clinically Significant Macular Edema
Status: Enrolling
Updated: 12/22/2015
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
mi
from
Halifax,
Click here to add this to my saved trials
Protein Kinase C (PKC) Inhibitor-Diabetic Retinopathy Phase 3 Study
Phase 3, Multicenter,Parallel,Randomized Dbl-masked,Placebo-controlled Study of the Effects of 32 mg/dy Ruboxistaurin Vision Loss in Patients With Type 1 or Type 2 Diabetes Mellitus and an Early Treatment Diabetic Retinopathy Study Level Between 47A and 53E.
Status: Enrolling
Updated:  12/22/2015
Clinical Research Facility
mi
from
Indianapolis, IN
Protein Kinase C (PKC) Inhibitor-Diabetic Retinopathy Phase 3 Study
Phase 3, Multicenter,Parallel,Randomized Dbl-masked,Placebo-controlled Study of the Effects of 32 mg/dy Ruboxistaurin Vision Loss in Patients With Type 1 or Type 2 Diabetes Mellitus and an Early Treatment Diabetic Retinopathy Study Level Between 47A and 53E.
Status: Enrolling
Updated: 12/22/2015
Clinical Research Facility
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Study of HUCNS-SC Subretinal Transplantation in Subjects With GA of AMD
A Phase II Proof-of-Concept Study of the Safety and Efficacy of HUCNS-SC Subretinal Transplantation in Subjects With Geographic Atrophy of Age-Related Macular Degeneration
Status: Enrolling
Updated:  12/23/2015
Retina Associates Southwest, PC
mi
from
Tucson, AZ
Study of HUCNS-SC Subretinal Transplantation in Subjects With GA of AMD
A Phase II Proof-of-Concept Study of the Safety and Efficacy of HUCNS-SC Subretinal Transplantation in Subjects With Geographic Atrophy of Age-Related Macular Degeneration
Status: Enrolling
Updated: 12/23/2015
Retina Associates Southwest, PC
mi
from
Tucson, AZ
Click here to add this to my saved trials
Study of HUCNS-SC Subretinal Transplantation in Subjects With GA of AMD
A Phase II Proof-of-Concept Study of the Safety and Efficacy of HUCNS-SC Subretinal Transplantation in Subjects With Geographic Atrophy of Age-Related Macular Degeneration
Status: Enrolling
Updated:  12/23/2015
Retina-Vitreous Associates Medical Group
mi
from
Beverly Hills, CA
Study of HUCNS-SC Subretinal Transplantation in Subjects With GA of AMD
A Phase II Proof-of-Concept Study of the Safety and Efficacy of HUCNS-SC Subretinal Transplantation in Subjects With Geographic Atrophy of Age-Related Macular Degeneration
Status: Enrolling
Updated: 12/23/2015
Retina-Vitreous Associates Medical Group
mi
from
Beverly Hills, CA
Click here to add this to my saved trials
Study of HUCNS-SC Subretinal Transplantation in Subjects With GA of AMD
A Phase II Proof-of-Concept Study of the Safety and Efficacy of HUCNS-SC Subretinal Transplantation in Subjects With Geographic Atrophy of Age-Related Macular Degeneration
Status: Enrolling
Updated:  12/23/2015
Retinal Diagnostic Center
mi
from
Campbell, CA
Study of HUCNS-SC Subretinal Transplantation in Subjects With GA of AMD
A Phase II Proof-of-Concept Study of the Safety and Efficacy of HUCNS-SC Subretinal Transplantation in Subjects With Geographic Atrophy of Age-Related Macular Degeneration
Status: Enrolling
Updated: 12/23/2015
Retinal Diagnostic Center
mi
from
Campbell, CA
Click here to add this to my saved trials
Study of HUCNS-SC Subretinal Transplantation in Subjects With GA of AMD
A Phase II Proof-of-Concept Study of the Safety and Efficacy of HUCNS-SC Subretinal Transplantation in Subjects With Geographic Atrophy of Age-Related Macular Degeneration
Status: Enrolling
Updated:  12/23/2015
Northern California Retina Vitreous Associates
mi
from
Mountain View, CA
Study of HUCNS-SC Subretinal Transplantation in Subjects With GA of AMD
A Phase II Proof-of-Concept Study of the Safety and Efficacy of HUCNS-SC Subretinal Transplantation in Subjects With Geographic Atrophy of Age-Related Macular Degeneration
Status: Enrolling
Updated: 12/23/2015
Northern California Retina Vitreous Associates
mi
from
Mountain View, CA
Click here to add this to my saved trials
Study of HUCNS-SC Subretinal Transplantation in Subjects With GA of AMD
A Phase II Proof-of-Concept Study of the Safety and Efficacy of HUCNS-SC Subretinal Transplantation in Subjects With Geographic Atrophy of Age-Related Macular Degeneration
Status: Enrolling
Updated:  12/23/2015
Retina Research Institute of Texas
mi
from
Palo Alto, CA
Study of HUCNS-SC Subretinal Transplantation in Subjects With GA of AMD
A Phase II Proof-of-Concept Study of the Safety and Efficacy of HUCNS-SC Subretinal Transplantation in Subjects With Geographic Atrophy of Age-Related Macular Degeneration
Status: Enrolling
Updated: 12/23/2015
Retina Research Institute of Texas
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Study of HUCNS-SC Subretinal Transplantation in Subjects With GA of AMD
A Phase II Proof-of-Concept Study of the Safety and Efficacy of HUCNS-SC Subretinal Transplantation in Subjects With Geographic Atrophy of Age-Related Macular Degeneration
Status: Enrolling
Updated:  12/23/2015
Rush University Medical Center
mi
from
Chicago, IL
Study of HUCNS-SC Subretinal Transplantation in Subjects With GA of AMD
A Phase II Proof-of-Concept Study of the Safety and Efficacy of HUCNS-SC Subretinal Transplantation in Subjects With Geographic Atrophy of Age-Related Macular Degeneration
Status: Enrolling
Updated: 12/23/2015
Rush University Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Study of HUCNS-SC Subretinal Transplantation in Subjects With GA of AMD
A Phase II Proof-of-Concept Study of the Safety and Efficacy of HUCNS-SC Subretinal Transplantation in Subjects With Geographic Atrophy of Age-Related Macular Degeneration
Status: Enrolling
Updated:  12/23/2015
William Beaumont Health System
mi
from
Royal Oak, MI
Study of HUCNS-SC Subretinal Transplantation in Subjects With GA of AMD
A Phase II Proof-of-Concept Study of the Safety and Efficacy of HUCNS-SC Subretinal Transplantation in Subjects With Geographic Atrophy of Age-Related Macular Degeneration
Status: Enrolling
Updated: 12/23/2015
William Beaumont Health System
mi
from
Royal Oak, MI
Click here to add this to my saved trials
Study of HUCNS-SC Subretinal Transplantation in Subjects With GA of AMD
A Phase II Proof-of-Concept Study of the Safety and Efficacy of HUCNS-SC Subretinal Transplantation in Subjects With Geographic Atrophy of Age-Related Macular Degeneration
Status: Enrolling
Updated:  12/23/2015
New York Eye & Ear Infirmary
mi
from
New York, NY
Study of HUCNS-SC Subretinal Transplantation in Subjects With GA of AMD
A Phase II Proof-of-Concept Study of the Safety and Efficacy of HUCNS-SC Subretinal Transplantation in Subjects With Geographic Atrophy of Age-Related Macular Degeneration
Status: Enrolling
Updated: 12/23/2015
New York Eye & Ear Infirmary
mi
from
New York, NY
Click here to add this to my saved trials
Study of HUCNS-SC Subretinal Transplantation in Subjects With GA of AMD
A Phase II Proof-of-Concept Study of the Safety and Efficacy of HUCNS-SC Subretinal Transplantation in Subjects With Geographic Atrophy of Age-Related Macular Degeneration
Status: Enrolling
Updated:  12/23/2015
Retina Research Institute of Texas, LLC
mi
from
Abilene, TX
Study of HUCNS-SC Subretinal Transplantation in Subjects With GA of AMD
A Phase II Proof-of-Concept Study of the Safety and Efficacy of HUCNS-SC Subretinal Transplantation in Subjects With Geographic Atrophy of Age-Related Macular Degeneration
Status: Enrolling
Updated: 12/23/2015
Retina Research Institute of Texas, LLC
mi
from
Abilene, TX
Click here to add this to my saved trials
Study of HUCNS-SC Subretinal Transplantation in Subjects With GA of AMD
A Phase II Proof-of-Concept Study of the Safety and Efficacy of HUCNS-SC Subretinal Transplantation in Subjects With Geographic Atrophy of Age-Related Macular Degeneration
Status: Enrolling
Updated:  12/23/2015
Retina Research Center
mi
from
Austin, TX
Study of HUCNS-SC Subretinal Transplantation in Subjects With GA of AMD
A Phase II Proof-of-Concept Study of the Safety and Efficacy of HUCNS-SC Subretinal Transplantation in Subjects With Geographic Atrophy of Age-Related Macular Degeneration
Status: Enrolling
Updated: 12/23/2015
Retina Research Center
mi
from
Austin, TX
Click here to add this to my saved trials